Analysts think GTBP stock price could increase by 5830%
Aug 02, 2024, 6:25 AM
-15.12%
What does GTBP do
GT Biopharma, Inc., a clinical stage biopharmaceutical company based in Brisbane, California, specializes in developing immuno-oncology therapeutics using its TriKE NK cell engager platform. Their main product, GTB-3550, targets cancer through a fusion protein that enhances natural killer cell efficacy, and is currently in Phase 1 trials for CD33-positive patients.
3 analysts think GTBP stock price will increase by 5830.23%. The current median analyst target is $153.00 compared to a current stock price of $2.58. The lowest analysts target is $151.50 and the highest analyst target is $157.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
